Essex Bio-Tech: April 2026 Monthly Return Shows Stable Share Capital and Full Public Float Compliance

Bulletin Express05-04

Essex Bio-Technology Limited filed its Monthly Return for the period ended 30 April 2026, confirming that both authorised and issued share capital remained unchanged during the month.

The company’s authorised share capital stood at 1.00 billion ordinary shares with a par value of HKD 0.10, representing total authorised capital of HKD 100 million. No increase or decrease was recorded.

Issued shares were steady at 567.01 million, with zero treasury shares outstanding. As a result, the total number of issued shares also remained at 567.01 million. Essex Bio-Tech confirmed compliance with the Hong Kong Main Board’s minimum public-float requirement of 25%.

Under the Share Option Scheme approved on 9 June 2023, no options were outstanding at month-end and no new shares were issued via option exercises. However, 57.06 million shares remain available for potential issuance under the scheme, providing future flexibility without diluting existing shareholders in the current period.

The filing reported no warrants, convertible securities, other share issuance arrangements, or movements in treasury shares.

The Monthly Return was submitted to Hong Kong Exchanges and Clearing Limited on 4 May 2026 and signed by Director Fang Haizhou.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150350482?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150350482","market":"us","top_or_hot":-1,"title":"Essex Bio-Tech: April 2026 Monthly Return Shows Stable Share Capital and Full Public Float Compliance","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited filed its Monthly Return for the period ended 30 April 2026, confirming that both authorised and issued share capital remained unchanged during the month.</p>\n<p>The company’s authorised share capital stood at 1.00 billion ordinary shares with a par value of HKD 0.10, representing total authorised capital of HKD 100 million. No increase or decrease was recorded.</p>\n<p>Issued shares were steady at 567.01 million, with zero treasury shares outstanding. As a result, the total number of issued shares also remained at 567.01 million. Essex Bio-Tech confirmed compliance with the Hong Kong Main Board’s minimum public-float requirement of 25%.</p>\n<p>Under the Share Option Scheme approved on 9 June 2023, no options were outstanding at month-end and no new shares were issued via option exercises. However, 57.06 million shares remain available for potential issuance under the scheme, providing future flexibility without diluting existing shareholders in the current period.</p>\n<p>The filing reported no warrants, convertible securities, other share issuance arrangements, or movements in treasury shares.</p>\n<p>The Monthly Return was submitted to Hong Kong Exchanges and Clearing Limited on 4 May 2026 and signed by Director Fang Haizhou.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Tech: April 2026 Monthly Return Shows Stable Share Capital and Full Public Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Tech: April 2026 Monthly Return Shows Stable Share Capital and Full Public Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-04 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited filed its Monthly Return for the period ended 30 April 2026, confirming that both authorised and issued share capital remained unchanged during the month.</p>\n<p>The company’s authorised share capital stood at 1.00 billion ordinary shares with a par value of HKD 0.10, representing total authorised capital of HKD 100 million. No increase or decrease was recorded.</p>\n<p>Issued shares were steady at 567.01 million, with zero treasury shares outstanding. As a result, the total number of issued shares also remained at 567.01 million. Essex Bio-Tech confirmed compliance with the Hong Kong Main Board’s minimum public-float requirement of 25%.</p>\n<p>Under the Share Option Scheme approved on 9 June 2023, no options were outstanding at month-end and no new shares were issued via option exercises. However, 57.06 million shares remain available for potential issuance under the scheme, providing future flexibility without diluting existing shareholders in the current period.</p>\n<p>The filing reported no warrants, convertible securities, other share issuance arrangements, or movements in treasury shares.</p>\n<p>The Monthly Return was submitted to Hong Kong Exchanges and Clearing Limited on 4 May 2026 and signed by Director Fang Haizhou.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1150350482","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150350482","pubTimestamp":1777885365,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited filed its Monthly Return for the period ended 30 April 2026, confirming that both authorised and issued share capital remained unchanged during the month. The company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"Essex Bio-Tech：2026年4月月度报告显示股本稳定且公众持股量完全合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited filed its Monthly Return for the period ended 30 April 2026, confirming that both authorised and issued share capital remained unchanged during the month.\nThe company’s authorised share capital stood at 1.00 billion ordinary shares with a par value of HKD 0.10, representing total authorised capital of HKD 100 million. No increase or decrease was recorded.\nIssued shares were steady at 567.01 million, with zero treasury shares outstanding. As a result, the total number of issued shares also remained at 567.01 million. Essex Bio-Tech confirmed compliance with the Hong Kong Main Board’s minimum public-float requirement of 25%.\nUnder the Share Option Scheme approved on 9 June 2023, no options were outstanding at month-end and no new shares were issued via option exercises. However, 57.06 million shares remain available for potential issuance under the scheme, providing future flexibility without diluting existing shareholders in the current period.\nThe filing reported no warrants, convertible securities, other share issuance arrangements, or movements in treasury shares.\nThe Monthly Return was submitted to Hong Kong Exchanges and Clearing Limited on 4 May 2026 and signed by Director Fang Haizhou.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150350482","isCrawlerRequest":true}